Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of ninerafaxstat in symptomatic non-obstructive hypertrophic cardiomyopathy
NL-OMON60688Phase 2Recruiting
- Sponsor
- Imbria Pharmaceuticals
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Ninerafaxstat with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. Started Apr 2026; status: recruiting.
02
Drugs
ninerafaxstat
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON60688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60688.